Effect of acarbose on glycemic variability in patients with poorly controlled type 2 diabetes mellitus receiving stable background therapy: A placebo-controlled trial

Giuseppe Derosa, Ivano Franzetti, Fabrizio Querci, Angela D'Angelo, Pamela Maffioli

Research output: Contribution to journalArticle

Abstract

Study Objective To evaluate the effect of acarbose on glycemic control and glycemic variability, using a continuous glucose-monitoring system, in patients with type 2 diabetes mellitus who were not well controlled on metformin and vildagliptin therapy. Design Multicenter, randomized, double-blind, placebo-controlled study. Setting Clinical research units at three hospitals in Italy. Patients Fifty-three patients with type 2 diabetes who were taking stable dosages of metformin 850 mg 3 times/day and vildagliptin 50 mg twice/day for at least 3 months and who were not adequately controlled with these therapies. Intervention Patients were randomized to either placebo or acarbose 100 mg 3 times/day to be added to their metformin-vildagliptin regimen. Measurements and Main Results Glycemic excursions were assessed by using a continuous glucose-monitoring system for 1 week. Glycemic control was estimated as the mean blood glucose (MBG) level, the area under the glucose concentration-time curve for a glucose level above 70 mg/dl (AUC above 70) or 180 mg/dl (AUC above 180), and the percentage of time that the glucose level was above 70 mg/dl (T above 70) or 180 mg/dl (T above 180). Intraday glycemic variability was assessed by the standard deviation of the blood glucose level, the mean amplitude of glycemic excursions (MAGE), the M value, and continuous overlapping net glycemic action. Day-to-day glycemic variability was assessed as the mean of daily difference (MODD). The MBG level was ~20 mg/dl lower in the acarbose group than in the placebo group (p

Original languageEnglish
Pages (from-to)983-990
Number of pages8
JournalPharmacotherapy
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • acarbose
  • continuous glucose-monitoring system
  • glycemic variability
  • vildagliptin

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of acarbose on glycemic variability in patients with poorly controlled type 2 diabetes mellitus receiving stable background therapy: A placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this